Literature DB >> 22472562

Distinct metabolic surrogates predict basal and rebound GH secretion after glucose ingestion in men.

Ali Iranmanesh1, Donna Lawson, Johannes D Veldhuis.   

Abstract

CONTEXT: GH secretion declines rapidly after glucose ingestion and then recovers to higher-than-baseline levels (rebound GH release). HYPOTHESIS: Selective metabolic markers predict the magnitude of glucose-suppressed GH release and postglucose rebound-like GH secretion.
DESIGN: Prospectively randomized crossover study of GH secretion after glucose vs. water ingestion.
SETTING: The study was conducted at a clinical translational research center. PARTICIPANTS: Sixty-nine healthy men aged 19-78 yr with a body mass index of 18-39 kg/m(2) participated in the study. OUTCOMES: OUTCOMES included nadir vs. peak GH concentrations and basal vs. pulsatile GH secretion.
RESULTS: Mean nadir GH concentrations were determined positively by sex hormone binding globulin (SHBG) after glucose administration (R(2) = 0.088, P = 0.0077). Peak rebound GH concentrations were related positively to adiponectin and negatively to computed tomography-estimated abdominal visceral fat (AVF) (R(2) = 0.182, P = 0.00049) after glucose ingestion. Deconvolution analysis showed that SHBG specifically predicted basal (nonpulsatile) GH secretion after glucose exposure (R(2) = 0.153, P = 0.00052). In contrast, together exercise history and adiponectin (both positively) and AVF (negatively) predicted pulsatile GH escape after glucose suppression (R(2) = 0.206, P = 0.00043). Moreover, adiponectin uniquely determined the size (mass), and AVF the mode (duration), of GH secretory bursts after glucose exposure (both P < 0.006).
CONCLUSION: Glucose ingestion provides a clinical model for investigating complementary metabolic surrogates that determine suppression and recovery of basal and pulsatile GH secretion in healthy men.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22472562      PMCID: PMC3387415          DOI: 10.1210/jc.2011-3317

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  38 in total

Review 1.  Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human.

Authors:  A Giustina; J D Veldhuis
Journal:  Endocr Rev       Date:  1998-12       Impact factor: 19.871

Review 2.  Clinical utility of sex hormone-binding globulin measurement.

Authors:  M Pugeat; J C Crave; J Tourniaire; M G Forest
Journal:  Horm Res       Date:  1996

3.  Diagnostic utility of the glucagon stimulation test in comparison to the insulin tolerance test in patients following pituitary surgery.

Authors:  Christian Berg; Timo Meinel; Harald Lahner; Ali Yuece; Klaus Mann; Stephan Petersenn
Journal:  Eur J Endocrinol       Date:  2009-12-08       Impact factor: 6.664

4.  Effects of oral glucose administration on spontaneous and growth hormone (GH)-releasing hormone-stimulated GH release in children and adults.

Authors:  R Valcavi; M Zini; C Volta; L Ghizzoni; C Azzarito; S Bernasconi; I Portioli
Journal:  J Clin Endocrinol Metab       Date:  1994-10       Impact factor: 5.958

5.  Relationships of circulating sex hormone-binding globulin with metabolic traits in humans.

Authors:  Andreas Peter; Konstantinos Kantartzis; Jürgen Machann; Fritz Schick; Harald Staiger; Fausto Machicao; Erwin Schleicher; Andreas Fritsche; Hans-Ulrich Häring; Norbert Stefan
Journal:  Diabetes       Date:  2010-09-14       Impact factor: 9.461

6.  Sensitivity and specificity of pulse detection using a new deconvolution method.

Authors:  Peter Y Liu; Daniel M Keenan; Petra Kok; Vasantha Padmanabhan; Kevin T O'Byrne; Johannes D Veldhuis
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-06-16       Impact factor: 4.310

7.  Metabolic modulation of the growth hormone-releasing activity of hexarelin in man.

Authors:  M Maccario; E Arvat; M Procopio; L Gianotti; S Grottoli; B P Imbimbo; V Lenaerts; R Deghenghi; F Camanni; E Ghigo
Journal:  Metabolism       Date:  1995-01       Impact factor: 8.694

8.  Impact of obesity on the growth hormone axis: evidence for a direct inhibitory effect of hyperinsulinemia on pituitary function.

Authors:  Raul M Luque; Rhonda D Kineman
Journal:  Endocrinology       Date:  2006-03-02       Impact factor: 4.736

9.  Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women.

Authors:  Cyril Y Bowers; Ramona Granda; Subburaman Mohan; Jonathan Kuipers; David Baylink; Johannes D Veldhuis
Journal:  J Clin Endocrinol Metab       Date:  2004-05       Impact factor: 5.958

10.  In obesity the somatotrope response to either growth hormone-releasing hormone or arginine is inhibited by somatostatin or pirenzepine but not by glucose.

Authors:  M Maccario; M Procopio; S Grottoli; S E Oleandri; P Razzore; F Camanni; E Ghigo
Journal:  J Clin Endocrinol Metab       Date:  1995-12       Impact factor: 5.958

View more
  5 in total

1.  Multipathway modulation of exercise and glucose stress effects upon GH secretion in healthy men.

Authors:  Johannes D Veldhuis; Thomas P Olson; Paul Y Takahashi; John M Miles; Michael J Joyner; Rebecca J Yang; Jean Wigham
Journal:  Metabolism       Date:  2015-05-15       Impact factor: 8.694

2.  Effect of oral glucose administration on rebound growth hormone release in normal and obese women: the role of adiposity, insulin sensitivity and ghrelin.

Authors:  Lara Pena-Bello; Sonia Pertega-Diaz; Elena Outeiriño-Blanco; Jesus Garcia-Buela; Sulay Tovar; Susana Sangiao-Alvarellos; Carlos Dieguez; Fernando Cordido
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

3.  Whole-body insulin sensitivity rather than body-mass-index determines fasting and post-glucose-load growth hormone concentrations.

Authors:  Christian-Heinz Anderwald; Andrea Tura; Alois Gessl; Sabina Smajis; Christian Bieglmayer; Rodrig Marculescu; Anton Luger; Giovanni Pacini; Michael Krebs
Journal:  PLoS One       Date:  2014-12-17       Impact factor: 3.240

4.  Sitagliptin Decreases Visceral Fat and Blood Glucose in Women With Polycystic Ovarian Syndrome.

Authors:  Jessica K Devin; Hui Nian; Jorge E Celedonio; Patricia Wright; Nancy J Brown
Journal:  J Clin Endocrinol Metab       Date:  2020-01-01       Impact factor: 5.958

5.  Eating, Sleep, and Social Patterns as Independent Predictors of Clinical, Metabolic, and Biochemical Behaviors Among Elite Male Athletes: The EROS-PREDICTORS Study.

Authors:  Flavio A Cadegiani; Claudio E Kater
Journal:  Front Endocrinol (Lausanne)       Date:  2020-06-26       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.